NASDAQ:ALEC Alector (ALEC) Stock Price, News & Analysis $1.74 +0.28 (+18.84%) As of 10:23 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Alector Stock (NASDAQ:ALEC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Alector alerts:Sign Up Key Stats Today's Range$1.54▼$1.7650-Day Range$1.35▼$1.7952-Week Range$0.87▼$6.37Volume349,127 shsAverage Volume727,323 shsMarket Capitalization$173.48 millionP/E RatioN/ADividend YieldN/APrice Target$4.17Consensus RatingHold Company Overview Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California. Read More Alector Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks83rd Percentile Overall ScoreALEC MarketRank™: Alector scored higher than 83% of companies evaluated by MarketBeat, and ranked 176th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingAlector has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on 4 buy ratings, 1 hold rating, and 2 sell ratings.Amount of Analyst CoverageAlector has only been the subject of 1 research reports in the past 90 days.Read more about Alector's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Alector are expected to decrease in the coming year, from ($1.88) to ($1.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alector is -1.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alector is -1.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlector has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.81% of the float of Alector has been sold short.Short Interest Ratio / Days to CoverAlector has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Alector has recently decreased by 5.02%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlector does not currently pay a dividend.Dividend GrowthAlector does not have a long track record of dividend growth. Sustainability and ESG4.5 / 5Environmental Score-0.92 Percentage of Shares Shorted7.81% of the float of Alector has been sold short.Short Interest Ratio / Days to CoverAlector has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Alector has recently decreased by 5.02%, indicating that investor sentiment is improving significantly. News and Social Media3.7 / 5News Sentiment0.60 News SentimentAlector has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Alector this week, compared to 3 articles on an average week.Search Interest2 people have searched for ALEC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows4 people have added Alector to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Alector insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,440.00 in company stock.Percentage Held by InsidersOnly 9.10% of the stock of Alector is held by insiders.Percentage Held by Institutions85.83% of the stock of Alector is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alector's insider trading history. Receive ALEC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alector and its competitors with MarketBeat's FREE daily newsletter. Email Address ALEC Stock News HeadlinesBrokerages Set Alector, Inc. (NASDAQ:ALEC) PT at $4.17August 8 at 2:53 AM | americanbankingnews.comAlector Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 7 at 4:18 PM | globenewswire.comIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.August 8 at 2:00 AM | Brownstone Research (Ad)Mizuho Upgrades Alector (ALEC) to Outperform, Raises PT to $3.50 on Q4 2025 Latozinemab Trial AnticipationAugust 1, 2025 | msn.comAlector, Inc. to Host Conference Call for Q2 2025 Results and Mid-Year Business UpdateJuly 31, 2025 | quiverquant.comQAlector to Host Second Quarter and Mid-Year 2025 Earnings Conference CallJuly 31, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA) and Alector (ALEC)July 30, 2025 | theglobeandmail.comMizuho Upgrades Alector (NASDAQ:ALEC) to "Outperform"July 30, 2025 | americanbankingnews.comSee More Headlines ALEC Stock Analysis - Frequently Asked Questions How have ALEC shares performed this year? Alector's stock was trading at $1.89 at the start of the year. Since then, ALEC stock has decreased by 17.6% and is now trading at $1.5570. How were Alector's earnings last quarter? Alector, Inc. (NASDAQ:ALEC) released its earnings results on Thursday, August, 7th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.15. The firm earned $7.87 million during the quarter, compared to the consensus estimate of $2.76 million. Alector had a negative net margin of 139.74% and a negative trailing twelve-month return on equity of 100.58%. Read the conference call transcript. Does Alector have any subsidiaries? Alector subsidiaries include Alector LLC. When did Alector IPO? Alector (ALEC) raised $177 million in an initial public offering on Thursday, February 7th 2019. The company issued 9,300,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays acted as the underwriters for the IPO. Who are Alector's major shareholders? Top institutional investors of Alector include Acadian Asset Management LLC (2.17%), TD Asset Management Inc (0.65%), Los Angeles Capital Management LLC (0.15%) and Bank of Montreal Can (0.05%). Insiders that own company stock include Polaris Venture Management Co, Arnon Rosenthal, Sara Kenkare-Mitra, Marc Grasso, Gary Romano, Kristine Yaffe and Paula Hammond. View institutional ownership trends. How do I buy shares of Alector? Shares of ALEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Alector own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alector investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Enovix (ENVX), Meta Platforms (META), Rambus (RMBS), Saia (SAIA) and Tesla (TSLA). Company Calendar Last Earnings8/07/2025Today8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALEC CIK1653087 Webwww.alector.com Phone(415) 231-5660FaxN/AEmployees270Year Founded2013Price Target and Rating Average Price Target for Alector$4.17 High Price Target$10.00 Low Price Target$1.00 Potential Upside/Downside+185.4%Consensus RatingHold Rating Score (0-4)2.29 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$119.05 million Net Margins-139.74% Pretax Margin-139.60% Return on Equity-100.58% Return on Assets-25.15% Debt Debt-to-Equity Ratio0.10 Current Ratio3.34 Quick Ratio3.34 Sales & Book Value Annual Sales$100.56 million Price / Sales1.45 Cash FlowN/A Price / Cash FlowN/A Book Value$1.29 per share Price / Book1.13Miscellaneous Outstanding Shares99,990,000Free Float90,894,000Market Cap$145.99 million OptionableOptionable Beta0.86 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:ALEC) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alector, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alector With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.